Literature DB >> 6259211

Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis.

M A Alspaugh, G Henle, E T Lennette, W Henle.   

Abstract

The frequencies and levels of antibodies to Epstein-Barr virus (EBV)-specific antigens were determined in paired sera and synovial fluids from patients with rheumatoid arthritis (RA) and in sera from patients with other connective tissue diseases; i.e., systemic lupus erythematosus, progressive systemic sclerosis, and osteoarthritis (OA). The specimens were also tested for the presence of antibodies to RA-associated nuclear antigen. Compared to healthy controls, the patients' sera showed increased frequencies of elevated antibody titers (>/=320) to Epstein-Barr viral capsid antigen, a correspondingly enhanced (twofold to threefold) geometric mean titer, and an increased frequency of antibodies at elevated titers (>/=10), usually to the restricted component and rarely the diffuse component of the early antigen complex. Levels of antibody to the EBV-associated nuclear antigen were within the normal range. Enhancement of antibody titers was more pronounced in seropositive RA patients (i.e., positive for rheumatoid factor) than in those who were not. Enhancement was also found in systemic lupus erythematosus and progressive systemic sclerosis. Antibody to RA-associated nuclear antigen was detected at an increased frequency only in the group of seropositive RA patients (90%), as compared to 8-15% in the other connective tissue diseases and 6-8% in healthy controls. The antibody titers in the synovial fluids equaled or were at most twofold higher or lower than those in the sera. In addition, levels of EBV-specific antibodies were studied serially over a period of 6-10 mo in patients with RA and OA. Parameters of disease activity were determined and compared to antibody levels. EBV-specific antibodies in sera of OA patients remained constant and within normal limits throughout the study. Although EBV-specific antibodies were often elevated in RA patients, they also remained constant, with the exception of three patients, who showed gradual increases in one of the four antibodies, which did not correlate with disease activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6259211      PMCID: PMC370674          DOI: 10.1172/jci110127

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence.

Authors:  M A Aslpaugh; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Jul-Aug

2.  Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; N Talal; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

3.  Clinical and laboratory aspects of raised virus antibody titres in systemic lupus erythematosus.

Authors:  N F Rothfield; A S Evans; J C Niederman
Journal:  Ann Rheum Dis       Date:  1973-05       Impact factor: 19.103

4.  Epstein-Barr virus (herpes-type virus) antibodies in connective tissue diseases.

Authors:  D A Stevens; M B Stevens; G R Newell; P H Levine; D E Waggoner
Journal:  Arch Intern Med       Date:  1972-07

5.  Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells.

Authors:  G Henle; W Henle; G Klein
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

6.  Antiviral antibodies in rheumatoid synovial fluid and cryoprecipitates.

Authors:  N E Cremer; D Hurwitz; F P Quismorio; E H Lennette; G J Friou
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

7.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

8.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

9.  Antibodies to cellular antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; E M Tan
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

10.  Virus antibody levels and delayed hypersensitivity in rheumatoid arthritis.

Authors:  P E Phillips; J Waxman; Y Hirshaut; M H Kaplan
Journal:  Ann Rheum Dis       Date:  1976-04       Impact factor: 19.103

View more
  64 in total

1.  Antibodies to Epstein-Barr viral antigens in familial rheumatoid arthritis.

Authors:  M McDermott; M Molloy; J Buckley; J Greally
Journal:  Ir J Med Sci       Date:  1989-08       Impact factor: 1.568

2.  Infectious aspects and the etiopathogenesis of rheumatoid arthritis.

Authors:  Michal Kasher Meron; Howard Amital; Daniel Shepshelovich; Ori Barzilai; Maya Ram; Juan-Manuel Anaya; Roberto Gerli; Nicola Bizzaro; Bizzaro Nicola; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

3.  Comparison of the immune response to Epstein-Barr virus and cytomegalovirus in sera and synovial fluids of patients with rheumatoid arthritis.

Authors:  M Musiani; M Zerbini; S Ferri; M Plazzi; G Gentilomi; M La Placa
Journal:  Ann Rheum Dis       Date:  1987-11       Impact factor: 19.103

4.  Increased frequency of antibodies to ubiquitous viruses in essential mixed cryoglobulinaemia.

Authors:  G Fiorini; P Bernasconi; R A Sinico; R Chianese; F Pozzi; G D'Amico
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

Review 5.  The clinical significance of posttranslational modification of autoantigens.

Authors:  Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

6.  Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation.

Authors:  Lixin Yang; Masayuki Hakoda; Kazuya Iwabuchi; Tsuyoshi Takeda; Takao Koike; Naoyuki Kamatani; Kenzo Takada
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis.

Authors:  G Tosato; A D Steinberg; R Yarchoan; C A Heilman; S E Pike; V De Seau; R M Blaese
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

8.  Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex.

Authors:  G Steiner; K Hartmuth; K Skriner; I Maurer-Fogy; A Sinski; E Thalmann; W Hassfeld; A Barta; J S Smolen
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Authors:  Mattias Magnusson; Mikael Brisslert; Kiandoht Zendjanchi; Magnus Lindh; Maria I Bokarewa
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

10.  Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis.

Authors:  A S Ferraro; M M Newkirk
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.